Ruti Aga's Six-Year Ban: The Prescription Was Forged, but the Case Was Decided on Paperwork, Not Pharmacology

A prescription slip. A clinic that did not exist. A “doctor” who was a family member with no medical registration. And an old prescription pad that the clinic explicitly disowned — a clinic that had never been part of it at all. That document decided Ruti Aga's career. Her sample came back positive after she won a half marathon in China in March. No time from that race was published, no splits, no field-strength report. The race was never the story. The story was the piece of paper she produced during the investigation, and which the Athletics Integrity Unit (AIU) dismantled in its statement. The statement records two separate matters at once: two years for presence of a prohibited substance, and four years for tampering. Six years in total, from 10 September. The athlete who won the 2026 Tokyo Marathon is now out of the sport from age thirty-two to age thirty-eight. Aga is not a marginal name. The 2026 Tokyo Marathon title is hers. Three second-place finishes at World Marathon Majors. Her career was built in the 2:18 to 2:20 band — the class where a place on the Ethiopian national team is never guaranteed, but where an appearance fee and a bonus are guaranteed at every major race in Europe and Asia. That was her economic position: Asian label races filling the gaps between Majors. For an Ethiopian marathoner it is the most sensible model available — few races, high appearance fees, low risk. And that exact tier has now become the AIU's highest-yield testing zone. The appearance-fee economy and the testing economy are colliding inside the same races. Understanding that collision requires one technical point that most of the reporting has missed. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid — class S9 on the WADA Prohibited List. And the decisive condition of S9 is that it is prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection given out of competition is entirely legal. A violation arises only when residues are present in an in-competition sample. That matters because it means Aga had a legitimate defence available. Route, timing and medical necessity were all arguable. Intra-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. That clinical argument could have been the spine of her case. What she did instead closed that route herself. The clinic named on the prescription did not exist. The person who wrote it was a family member, not a registered physician. And when that person claimed to have used “an old prescription pad from a former workplace,” the clinic itself came forward and disowned the claim. Three independent verification failures inside a single document. There is a simple logic that explains the whole case: if the treatment really happened, it would have been defended with real records. A forged prescription comes from someone who has nothing real to show. From my first season running Delhi State cross-country I learned that a race is not decided at the finish line but in the paperwork filed before it. Twenty-two years of reading results wires and start lists has only confirmed it: the tape shows you the race, the paperwork shows you the asterisk. Now the arithmetic of the sanction. Two years for presence, four for tampering. That is the Code's standard architecture: a two-year presence sanction is what you get when the substance is a Specified one and intent is unproven. Four years is the standard tampering sanction. Adding them together tells us the panel refused the no-significant-fault mitigation that would otherwise have shortened the presence sanction. Backdating to 10 September is not a reduction. It is a procedural benefit. Time served under provisional suspension counts against the ban. In real terms the athlete gains nothing. The four-year tampering charge did not come from a document alone but from an interview — from statements given under questioning. Language and translation conditions in AIU interviews have been a recurring point of contention, especially when the athlete is not being questioned in her first language. That narrows the room for a defence rather than widening it, but it belongs in the record. The career arithmetic is harsher still. Six years from thirty-two means a return at thirty-eight. Ethiopian women's marathon depth is such that no federation selector will pick a thirty-eight-year-old with a doping record. The entire 2028 Olympic cycle is gone. In practice this is a lifetime ban; on paper it is six years. One thing survives — the 2026 Tokyo title. The violation is anchored to the March race. Absent a finding of earlier use, results before that date are not automatically annulled. The AIU statement does not state the disqualification scope, but standard practice voids the result and prize money of the competition where the sample was collected, along with ranking points accrued after it. And here the real question surfaces, and it is about paperwork more than pharmacology. I went back to the tape to find the moment everyone missed — except there is no tape here, only files. And the files say this is a medical-governance failure, not merely one runner's deceit. The knee injury is the true starting point. An injured marathoner faces pressure to mask pain to protect appearance-fee income; a glucocorticoid is the cheapest and most available tool for that; and the surrounding medical network is informal. No credentialed team physician appears anywhere in the chain, and no TUE infrastructure either. Where there is no TUE framework, prescriptions get manufactured. The accepted story is clean: cheat caught, six years, deterrence works. I would argue that is the second-most-important thing here. The most important thing is that the six years were awarded for the document, not the drug. The second post is where the real story usually hides — here, the second post is the sentence carrying the number four. Apply a falsification test: what evidence would prove the clean story right? Three things — an anabolic steroid (S1) finding in the sample; a panel finding of intent to enhance performance; or a real clinic confirming a real prescription. Not one of the three is in the record. So the clean story is wrong — which does not make the inverted story right either. The truth sits in between: a therapeutic drug, bad advice, and a document that destroyed the only defence that could have worked. The second thing nobody is saying: only the family member is named. Whether the agent, manager or coach who saw, accepted or suggested that prescription was ever investigated is unknown. Follow the money, then follow the people it forgot. An athlete does not make these decisions alone; she makes them inside a network that sets her race schedule. No allegation has been made against the network. The third thing: a glucocorticoid whose endurance benefit is itself disputed drew six years. That number will be cited from both directions — as proof of AIU rigour, and as proof of inconsistent enforcement against African road runners. The next step is clear: an appeal window to the Court of Arbitration for Sport, typically twenty-one days from the reasoned decision. A document-based finding is hard to overturn. What to watch is why the Ethiopian federation has stayed silent, when the March result is formally annulled, and whether anyone investigates the network that decided a prescription was necessary. A microphone can disappear in a week; a voice takes longer. In this case we heard the AIU's voice, not the athlete's. Because who writes the next prescription is a bigger question than the drug.